Profile data is unavailable for this security.
About the company
P3 Health Partners Inc. is a patient-centered and physician-led population health management company. The Company supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, it creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system. Its technology platform, P3 Technology/Health Hub, enables physicians, care teams, patients and their family members to engage in the care journey. P3 Technology/Health Hub integrates clinical and claims data from more than 250 disparate data points each month from payors, outpatient and inpatient facilities and other ancillary care settings. It has a network of more than 2,800 affiliated primary care providers across the country. Its local teams of health care professionals manage the care of thousands of patients in 23 counties across five states.
- Revenue in USD (TTM)1.40bn
- Net income in USD-69.48m
- Incorporated2020
- Employees400.00
- LocationP3 Health Partners Inc2045 W Grand Ave Ste B, Pmb # 82152CHICAGO 60612-1577United StatesUSA
- Phone+1 (312) 822-8897
- Fax+1 (302) 636-5454
- Websitehttps://ir.p3hp.org/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Skye Bioscience Inc | 0.00 | -42.29m | 158.97m | 11.00 | -- | 2.02 | -- | -- | -3.91 | -3.91 | 0.00 | 2.59 | 0.00 | -- | -- | 0.00 | -94.50 | -232.67 | -129.40 | -- | -- | -- | -- | -- | -- | -323.10 | 0.0626 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
| Tenaya Therapeutics Inc | 0.00 | -120.74m | 159.36m | 140.00 | -- | 1.19 | -- | -- | -1.54 | -1.54 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -62.89 | -- | -69.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
| Seres Therapeutics Inc | 374.00k | -162.11m | 160.00m | 233.00 | -- | -- | -- | 427.81 | -1.18 | -1.18 | 0.0027 | -0.5742 | 0.001 | -- | 0.0286 | 1,605.15 | -44.53 | -41.51 | -59.82 | -54.13 | -- | -- | -43,343.58 | -170.14 | 0.889 | -17.64 | 6.65 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
| Immunic Inc | 0.00 | -95.31m | 161.24m | 77.00 | -- | 2.54 | -- | -- | -1.51 | -1.51 | 0.00 | 0.7058 | 0.00 | -- | -- | 0.00 | -108.78 | -72.09 | -141.92 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
| Ventyx Biosciences Inc | 0.00 | -171.30m | 161.83m | 73.00 | -- | 0.5763 | -- | -- | -2.79 | -2.79 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -52.07 | -- | -55.27 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
| P3 Health Partners Inc | 1.40bn | -69.48m | 164.55m | 400.00 | -- | 0.446 | -- | 0.1173 | -0.5821 | -0.5821 | 11.56 | 1.03 | 1.56 | -- | 10.97 | 3,507,143.00 | -20.51 | -- | -110.70 | -- | 0.6223 | 0.1781 | -13.17 | -56.93 | -- | -9.67 | 0.2686 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
| Lineage Cell Therapeutics Inc | 6.19m | -24.19m | 166.18m | 75.00 | -- | 2.43 | -- | 26.86 | -0.1342 | -0.1342 | 0.0343 | 0.3617 | 0.0577 | -- | 18.25 | 82,480.00 | -22.57 | -19.53 | -26.03 | -22.59 | 90.83 | 89.13 | -391.25 | -370.88 | -- | -- | 0.0017 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
| Capricor Therapeutics Inc | 27.15m | -27.95m | 166.60m | 101.00 | -- | 14.24 | -- | 6.14 | -0.9302 | -0.9302 | 0.9072 | 0.3596 | 0.6443 | -- | 59.18 | 268,833.90 | -66.31 | -54.12 | -208.71 | -75.13 | -- | -- | -102.93 | -316.25 | -- | -- | 0.2269 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
| Galectin Therapeutics Inc | 0.00 | -48.03m | 168.77m | 14.00 | -- | -- | -- | -- | -0.7831 | -0.7831 | 0.00 | -1.32 | 0.00 | -- | -- | 0.00 | -185.54 | -92.08 | -382.33 | -121.97 | -- | -- | -- | -- | -- | -8.59 | 8.29 | -- | -- | -- | -15.26 | -- | -- | -- |
| Generation Bio Co | 13.17m | -158.43m | 172.86m | 174.00 | -- | 1.50 | -- | 13.12 | -2.39 | -2.39 | 0.1989 | 1.73 | 0.0393 | -- | 77.49 | 75,712.64 | -47.28 | -36.96 | -51.64 | -39.21 | -- | -- | -1,202.56 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
| Shattuck Labs Inc | 4.12m | -85.28m | 174.20m | 75.00 | -- | 1.57 | -- | 42.24 | -1.85 | -1.85 | 0.0883 | 2.32 | 0.029 | -- | -- | 54,986.67 | -60.08 | -29.14 | -66.66 | -32.42 | -- | -- | -2,067.99 | -565.33 | -- | -- | 0.00 | -- | 154.14 | -40.62 | 14.37 | -- | -19.15 | -- |
| Sangamo Therapeutics Inc | 12.28m | -249.68m | 174.30m | 405.00 | -- | 7.36 | -- | 14.20 | -1.38 | -1.38 | 0.0664 | 0.1138 | 0.0587 | -- | 7.45 | 30,313.58 | -119.44 | -26.09 | -153.51 | -31.04 | -- | -- | -2,033.68 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
| Inovio Pharmaceuticals Inc | 591.86k | -121.64m | 175.78m | 122.00 | -- | 1.82 | -- | 296.99 | -5.11 | -5.11 | 0.0248 | 3.73 | 0.0032 | -- | 0.6652 | 4,851.31 | -66.32 | -59.52 | -84.33 | -71.29 | -- | -- | -20,552.24 | -4,097.36 | -- | -- | 0.00 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
Data as of Sep 19 2024. Currency figures normalised to P3 Health Partners Inc's reporting currency: US Dollar USD
22.05%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Alyeska Investment Group LPas of 30 Jun 2024 | 15.95m | 9.86% |
| Armistice Capital LLCas of 30 Jun 2024 | 7.90m | 4.88% |
| Columbia Wanger Asset Management LLCas of 30 Jun 2024 | 6.32m | 3.91% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.80m | 1.12% |
| EMFO LLCas of 30 Jun 2024 | 1.43m | 0.88% |
| Millennium Management LLCas of 30 Jun 2024 | 594.36k | 0.37% |
| Geode Capital Management LLCas of 30 Jun 2024 | 478.33k | 0.30% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Jun 2024 | 476.72k | 0.30% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 409.77k | 0.25% |
| Jane Street Capital LLCas of 30 Jun 2024 | 308.48k | 0.19% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
